CD8A and hepatocellular carcinoma: Chuah et al. identified circulating CXCR3 expressing CD8+ T cells as biomarkers for response to anti-PD-1 in patients with hepatocellular cancer, assigning CXCR3 not only to a role as prognostic marker of recurrence but also as a marker of response to anti-PD1 therapy [51].